drugset / Trial / NCT02182518

Epinastine + Pseudoephedrine SR (Slow Release) Versus Epinastine Alone in Patients With Perennial Allergic Rhinitis

NCT02182518

Phase 3 Completed 101 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this trial is to evaluate the clinical efficacy and safety of Epinastine 10 mg + Pseudoephedrine 120 mg slow release (SR) administered twice a day, compared to Epinastine 10 mg alone administered twice daily.

Timeline

Start
2000-05
Primary completion
2001-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Epinastine Small molecule 10 mg
Subject Pseudoephedrine Small molecule 120 mg